Virax Biolabs Group Stock Analysis

Virax Stock Analysis Notes

The company has Price to Book (P/B) ratio of 1.04. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Virax Biolabs Group recorded a loss per share of 2.61. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 18th of December 2023. Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom. Virax Biolabs is traded on NASDAQ Exchange in the United States. For more information please call James Foster at 44 20 7788 7414 or visit https://viraxbiolabs.com.

Virax Biolabs Group Investment Alerts

Virax Biolabs Group Upcoming and Recent Events

Virax Biolabs Environmental, Social, and Governance (ESG) Scores

Virax Biolabs Thematic Classifications

Virax Stock Institutional Investors

Note, although Virax Biolabs' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Virax Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.99 M.

Virax Profitablity

Management Efficiency

Virax Biolabs Group has return on total asset (ROA) of (0.499) % which means that it has lost $0.499 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9598) %, meaning that it created substantial loss on money invested by shareholders. Virax Biolabs' management efficiency ratios could be used to measure how well Virax Biolabs manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.3 in 2024. Return On Capital Employed is likely to rise to -1.16 in 2024. At this time, Virax Biolabs' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 1.2 M in 2024, whereas Total Assets are likely to drop slightly above 3.4 M in 2024.

Technical Drivers

As of the 29th of November, Virax Biolabs has the Risk Adjusted Performance of (0.07), variance of 83.12, and Coefficient Of Variation of (981.29). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Virax Biolabs Group, as well as the relationship between them.

Virax Biolabs Group Price Movement Analysis

Virax Biolabs Predictive Daily Indicators

Virax Biolabs Corporate Filings

Virax Biolabs Forecast Models

Virax Biolabs' time-series forecasting models are one of many Virax Biolabs' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Virax Biolabs' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Virax Biolabs prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Virax shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Virax Biolabs. By using and applying Virax Stock analysis, traders can create a robust methodology for identifying Virax entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Virax analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Virax analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Virax Biolabs Group stock analysis indicators help investors evaluate how Virax Biolabs stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Virax Biolabs shares will generate the highest return on investment. By understating and applying Virax Biolabs stock analysis, traders can identify Virax Biolabs position entry and exit signals to maximize returns.

When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.